openPR Logo
Press release

Lesstopy ATO Cream Expands into 11 Department Stores Across Korea, Including Shinsegae and Lotte

09-10-2025 07:38 PM CET | Politics, Law & Society

Press release from: ABNewswire

Lesstopy ATO Cream

Lesstopy ATO Cream

Korean skincare brand Lesstopy has entered 11 Babea-Papa stores in major department stores including Shinsegae Gangnam and Suwon Starfield, marking significant offline expansion. Based on anatomical skin research, Lesstopy Ato Cream features patented Lycopus Lucidus Leaf Extract with 23% certified organic ingredients and international COSMOS certification. The brand has validated product safety and efficacy through over 10 clinical studies, including infant safety evaluations.
Seoul, Korea - Skincare brand Lesstopy has entered 11 Babea-Papa stores located in major department stores across Korea-including Shinsegae Department Store Gangnam and Suwon Starfield-marking a significant expansion of its offline distribution network.

Originating from anatomical research on human skin structure, Lesstopy offers soothing, moisture-focused care for sensitive and delicate skin. Its flagship product, Lesstopy Ato Cream, features a patented Lycopus Lucidus Leaf Extract (Shibssari Leaf Extract) as a key ingredient, designed to gently envelop and calm irritated skin.

The formula contains 23% certified organic ingredients, earning the brand the prestigious international COSMOS certification through KTR, a leading organic cosmetics certification body. This certification ensures compliance with rigorous global standards from formulation to manufacturing.

Lesstopy has validated the safety and efficacy of its products through over 10 clinical studies-including infant safety evaluations-and various global certifications, demonstrating proven benefits in hydration, barrier reinforcement, and skin-soothing effects.

A Lesstopy representative stated, "Lesstopy is not just an organic brand, but a care brand built on anatomy-based skin-soothing science. This expansion into department stores offers consumers a meaningful opportunity to experience our philosophy and product efficacy both online and offline."

Media Contact
Company Name: Glovertise
Contact Person: Erick
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lesstopy-ato-cream-expands-into-11-department-stores-across-korea-including-shinsegae-and-lotte]
Phone: 01091916367
Address:8, Yeongdong-daero 112-gil #505
City: Gangnam-gu
State: Seoul
Country: South Korea
Website: http://glovertise.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lesstopy ATO Cream Expands into 11 Department Stores Across Korea, Including Shinsegae and Lotte here

News-ID: 4177993 • Views:

More Releases from ABNewswire

California Libraries Now Offer Free Ecosense EcoBlu Radon Monitors Through CDPH Program
California Libraries Now Offer Free Ecosense EcoBlu Radon Monitors Through CDPH …
A new statewide initiative expands radon awareness and provides residents with free, easy-to-use digital testing devices. Ecosense [https://ecosense.io/] announced its partnership with the California Department of Public Health (CDPH) Indoor Radon Program [https://www.cdph.ca.gov/Programs/CEH/DRSEM/Pages/EMB/Radon/Radon.aspx] to provide digital radon detection technology to all residents throughout the state. Through the U.S. Environmental Protection Agency's State Indoor Radon Grant (SIRG), CDPH acquired 600 Ecosense EcoBlu digital radon monitors, now deployed across 21 public library systems
Breast Cancer Clinical Trial Pipeline Gains Momentum: 250+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Breast Cancer Clinical Trial Pipeline Gains Momentum: 250+ Companies Lead the Ch …
DelveInsight's "Breast Cancer Pipeline Insight 2025" report provides comprehensive insights about 250+ Breast Cancer companies and 300+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest
Wiskott-Aldrich Syndrome Clinical Trial Pipeline Expands as 5+ Companies Driving Innovation in the Therapeutics | DelveInsight
Wiskott-Aldrich Syndrome Clinical Trial Pipeline Expands as 5+ Companies Driving …
DelveInsight's "Wiskott-Aldrich Syndrome Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Wiskott-Aldrich Syndrome pipeline landscape. It covers the Wiskott-Aldrich Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wiskott-Aldrich Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment
Dilated Cardiomyopathy Treatment Pipeline Shows Strong Momentum as 8+ Pharma Companies in the Race | DelveInsight
Dilated Cardiomyopathy Treatment Pipeline Shows Strong Momentum as 8+ Pharma Com …
DelveInsight's "Dilated Cardiomyopathy Pipeline Insight 2025" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Dilated Cardiomyopathy pipeline landscape. It covers the Dilated Cardiomyopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dilated Cardiomyopathy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment

All 5 Releases